Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
JOHNSON & JOHNSON MEDTECH LAUNCHES NEW PRESBYOPIA-CORRECTING INTRAOCULAR LENS TECNIS PURESEE IN EMEA | ||
By: GlobeNewswire - 15 Feb 2024 | Back to overview list |
|
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision LIMERICK, IRELAND, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Johnson & Johnson MedTech*, a global leader in eye health, announced today that its TECNIS PureSee purely refractive presbyopia-correcting lens is now available in EMEA. The TECNIS PureSee IOL features a proprietary, purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-category contrast and low-light performance, comparable to a monofocal IOL1,2,3,4. “Cataract surgery is the number one surgery performed globally, with 28 million procedures each year. But only 10-15% of patients are getting advanced optical IOLs specifically designed for astigmatism and presbyopia10,” said Jacqueline Henderson, President Vision, EMEA, Johnson & Johnson. “Today, we’re proud to launch the TECNIS PureSee IOL, giving surgeons and patients the choice of a premium IOL that combines clarity of vision and reduced visual symptoms10.” Today, when choosing an IOL, surgeons and patients must make trade-off decisions. For example, you can have a lens that offers clear sight at all distances without spectacles, but at the price of possible glares and halos. TECNIS PureSee combats these issues and improves the overall outcomes for both patients and surgeons. 2,3,8,10,11 “A key concern for patients who chose a premium IOL is whether their vision correction surgery meets their expectations both in regard to the level of spectacle independence** and quality of vision. My early experience with the TECNIS PureSee IOL has been extremely positive and has consistently delivered on these expectations resulting in very happy patients,” said Dr. Francesco Carones, Medical Director & Physician CEO Advalia Vision, Milano, Italy***. “I’ve found that this new refractive PC-IOL reliably delivers consistent, uninterrupted, high-quality vision with excellent distance vision and high contrast not only in daylight but also at night 1,2,3,7. Together with the low level of dysphotopsia, that is comparable to a monofocal IOL3,11,12, these are exactly the results my patients are looking for. So, I’m thrilled to be able to offer them the ability to correct presbyopia with this new lens technology.” With its purely refractive design, the TECNIS PureSee IOL ensures surgeons’ ease of use in providing high tolerance to refractive error. The TECNIS PureSee IOL offers important benefits to both surgeons and their patients, including:
Cataracts are the leading cause of treatable blindness in the world9. Today, a surgeon can remove a cataract and replace it with an IOL, with patients typically experiencing improved sight the very same day. The TECNIS PureSee IOL is now available in select markets in EMEA. #### About Johnson & Johnson MedTech* At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook. IMPORTANT SAFETY INFORMATION - EMEA Cautions Concerning Forward-Looking Statements *Johnson & Johnson MedTech represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both. References:
©Johnson & Johnson Surgical Vision, Inc. 2024 2024PP04236 Attachment CONTACT: Media contact: Sally Hetherington Johnson & Johnson MedTech shether1@its.jnj.com +44 7770 337800 |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |